EUVIMEDEUVIMED entdecken
Crossref

Chromobox 4 interacts with pregnane X receptor to repress CYP3A4 expression through polycomb repressive complex 1/2–mediated epigenetic regulation

Ibuki Kamiyoshihara, Masataka Nakano, Itsuki Yokoseki, Mei Tomii, Yuichiro Higuchi, Shotaro Uehara, Nao Yoneda, Hiroshi Suemizu, Tatsuki Fukami, Miki Nakajima

Drug Metabolism and Disposition · 2026

DOI: 10.1016/j.dmd.2026.100387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026. Verfasst von Ibuki Kamiyoshihara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Pregnane X Receptor, Epigenesis, Genetic, Receptors, Steroid. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Government of Japan Ministry of Education Culture Sports Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycomb repressive complexes (PRCs) 1 and 2 are epigenetic regulators that suppress gene transcription through histone H3 lysine K27 trimethylation. This modification, catalyzed by enhancer of zeste homolog 2 (EZH2) within PRC2, is recognized by chromobox (CBX) proteins within PRC1, leading to chromatin condensation and transcriptional repression. Although EZH2 and CBX inhibitors have been developed for cancer therapy, the role of PRC1/2 inhibition in the regulation of drug metabolism-related genes remains unclear. In this study, we investigated the regulatory mechanisms of CYP3A4 expression by PRC1/2. Treatment with GSK126, an EZH2 inhibitor, significantly increased CYP3A4 mRNA and protein levels in HepaSH cells and ShP51 cells. Among CBX family members, CBX4 knockdown increased CYP3A4 mRNA levels, whereas its overexpression suppressed them in ShP51 cells. Consistently, CBX4 knockdown enhanced rifampicin-induced CYP3A4 expression, whereas its overexpression attenuated this induction. A coimmunoprecipitation assay revealed that CBX4 interacts with pregnane X receptor (PXR) regardless of rifampicin treatment. Chromatin immunoprecipitation analysis demonstrated that both CBX4 and PXR bind to the promoter and enhancer regions of CYP3A4, and that CBX4 knockdown increases PXR binding. Formaldehyde-assisted isolation of regulatory elements assays showed that CBX4 knockdown relaxed chromatin structure at the CYP3A4 locus, which is further enhanced by rifampicin. Collectively, these findings indicate that CBX4 interacts with PXR and likely represses CYP3A4 transcription through recognition of EZH2-mediated trimethylation of lysine 27 on histone H3 and chromatin condensation, highlighting a potential risk of drug-drug interactions associated with CBX4 inhibition. SIGNIFICANCE STATEMENT: This study provides, to our knowledge, the first evidence of epigenetic mechanisms underlying CYP3A4 suppression mediated by PRC1/2. The findings demonstrate that CBX4 interacts with PXR and binds to the CYP3A4 regulatory regions, where it recognizes enhancer of zeste homolog 2-mediated trimethylation of lysine 27 on histone H3 and represses CYP3A4 transcription via chromatin condensation. Given the increasing clinical interest in CBX inhibitors for cancer therapy, these findings highlight a potential risk of drug-drug interactions associated with CBX4 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3APregnane X ReceptorEpigenesis, GeneticReceptors, SteroidPolycomb Repressive Complex 2Polycomb Repressive Complex 1HumansEnhancer of Zeste Homolog 2 ProteinCell Line, TumorPromoter Regions, GeneticLigasesPolycomb-Group Proteins

Stichwörter der Autor:innen

CBX4CYP3A4Cytochrome P450sEpigenetic regulationPRC1/2PXR

Substanzen

Cytochrome P-450 CYP3APregnane X ReceptorCYP3A4 protein, humanReceptors, SteroidCBX4 protein, humanPolycomb Repressive Complex 2Polycomb Repressive Complex 1Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanLigases

Autor:innen und Institutionen

  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.…
  • Liver Engineering Laboratory, Department of Research for Humanized Model, Central Institute for Experimental Medicine and Life Science (CIEM), Kanagawa, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.

Förderung

  • Government of Japan Ministry of Education Culture Sports Science and Technology

Zitieren

APA

Kamiyoshihara, I., Nakano, M., Yokoseki, I., Tomii, M., Higuchi, Y., Uehara, S., Yoneda, N., Suemizu, H., Fukami, T., & Nakajima, M. (2026). Chromobox 4 interacts with pregnane X receptor to repress CYP3A4 expression through polycomb repressive complex 1/2–mediated epigenetic regulation. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2026.100387

Vancouver

Kamiyoshihara I, Nakano M, Yokoseki I, Tomii M, Higuchi Y, Uehara S, et al. Chromobox 4 interacts with pregnane X receptor to repress CYP3A4 expression through polycomb repressive complex 1/2–mediated epigenetic regulation. Drug Metabolism and Disposition. 2026. doi:10.1016/j.dmd.2026.100387

BibTeX
@article{Kamiyoshihara2026,
  author = {Kamiyoshihara, Ibuki and Nakano, Masataka and Yokoseki, Itsuki and Tomii, Mei and Higuchi, Yuichiro and Uehara, Shotaro and Yoneda, Nao and Suemizu, Hiroshi and Fukami, Tatsuki and Nakajima, Miki},
  title = {Chromobox 4 interacts with pregnane X receptor to repress CYP3A4 expression through polycomb repressive complex 1/2–mediated epigenetic regulation},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  doi = {10.1016/j.dmd.2026.100387}
}
Kostenlos starten →